Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immix Biopharma, Inc. (IMMX)
NASDAQ:IMMX
IMMX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.26 - $3.80
Previous Close$2.25
Volume74.23K
Average Volume (3M)82.28K
Market Cap
$48.96M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.75
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.88
Shares Outstanding27,507,637
10 Day Avg. Volume88,783
30 Day Avg. Volume82,277
Standard Deviation0.31
R-Squared0.00136
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$7.00Price Target Upside297.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsUpdated results from the NEXICART-1 trial show NXC-201 elicited a 94% overall response rate (ORR) and a 75% complete response (CR) rate in 16 patients.
FDA DesignationThe FDA granted RMAT designation to NXC-201, which is being evaluated in NEXICART-2 trial for the treatment of relapsed/refractory AL Amyloidosis.
Market PotentialThere is a forecast for peak global sales of NXC-201 to reach approximately $525 million, underlining strong market potential.
Bears Say
Efficacy ConcernsRisks include poorer-than-anticipated efficacy in later-stage trials, unanticipated safety and immunogenicity concerns, unexpected challenges in manufacturing, superior clinical data from competitor agents, and possible near-term stock dilution.
Safety And Manufacturing RisksRisks for Immix Biopharma include potential safety concerns, manufacturing challenges, and competition from other clinical agents.
---
Ownership Overview
40.45% Insiders
3.13% Mutual Funds
6.23% Other Institutional Investors
47.61% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IMMX FAQ
What was Immix Biopharma, Inc.’s price range in the past 12 months?
Immix Biopharma, Inc. lowest stock price was $1.26 and its highest was $3.80 in the past 12 months.
What is Immix Biopharma, Inc.’s market cap?
Immix Biopharma, Inc.’s market cap is $48.96M.
When is Immix Biopharma, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Immix Biopharma, Inc.’s earnings last quarter?
Currently, no data Available
Is Immix Biopharma, Inc. overvalued?
According to Wall Street analysts Immix Biopharma, Inc.’s price is currently Undervalued.
Does Immix Biopharma, Inc. pay dividends?
Immix Biopharma, Inc. does not currently pay dividends.
What is Immix Biopharma, Inc.’s EPS estimate?
Immix Biopharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immix Biopharma, Inc. have?
Immix Biopharma, Inc. has 27,507,637 shares outstanding.
What happened to Immix Biopharma, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Immix Biopharma, Inc.?
Currently, no hedge funds are holding shares in IMMX
---
Immix Biopharma, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (297.73% Upside)
$7.00 (297.73% Upside)
Hedge Fund Trend
Decreased
By 27.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $104.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 6.5%
Last 30 Days ▼ 6.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.13%
12-Months-Change
Fundamentals
Return on Equity
-117.30%
Trailing 12-Months
Asset Growth
11.87%
Trailing 12-Months
Company Description
Immix Biopharma, Inc.
Immix Biopharma Inc is a clinical-stage biopharmaceutical company developing Tissue-Specific Therapeutics in oncology and inflammation.
---
IMMX Stock 12 Month Forecast
Average Price Target
$7.00
▲(297.73% Upside)
Technical Analysis
Best Analysts Covering IMMX
1 Year
1 Year Success Rate
1/5 ratings generated profit
1 Year Average Return
-7.42%
reiterated a buy rating 12 days ago
Copying Robert Burns's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -7.42% per trade.
---